Showing posts with label ovarian cancer. Show all posts
Showing posts with label ovarian cancer. Show all posts

Sunday, February 17, 2013

Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.


Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.


Feb 2013


Source

C Olsen, Cancer Control Group, Queensland Institute of Medical Research, Brisbane, Australia.

Abstract

Whilst previous studies have reported that higher body-mass index (BMI) increases a woman's risk of developing ovarian cancer, associations for the different histological subtypes have not been well defined. As the prevalence of obesity has increased dramatically, and classification of ovarian histology has improved in the last decade, we sought to examine the association in a pooled analysis of recent studies participating in the Ovarian Cancer Association Consortium. We evaluated the association between BMI (recent, maximum, and in young adulthood) and ovarian cancer risk using original data from 15 case-control studies (13,548 cases, 17,913 controls). We combined study-specific adjusted odds ratios (ORs) using a random-effects model. We further examined the associations by histological subtype, menopausal status and post-menopausal hormone use. High BMI (all time-points) was associated with increased risk. This was most pronounced for borderline serous (recent BMI: pooled OR=1.24 per 5kg/m2; 95%CI 1.18-1.30), invasive endometrioid (1.17; 1.11-1.23) and invasive mucinous (1.19; 1.06-1.32) tumours. There was no association with serous invasive cancer overall (0.98; 0.94-1.02), but increased risks for low grade serous invasive tumours (1.13, 1.03-1.25) and in pre-menopausal women (1.11; 1.04-1.18). Among post-menopausal women, the associations did not differ between HRT users and non-users. Whilst obesity appears to increase risk of the less common histological subtypes of ovarian cancer, it does not increase risk of high grade invasive serous cancers, and reducing BMI is therefore unlikely to prevent the majority of ovarian cancer deaths. Other modifiable factors must be identified to control this disease.

Friday, February 8, 2013

New surgery helps prevent ovarian cancer


New surgery helps prevent ovarian cancer


KGW Staff
Posted on February 7, 2013 at 3:59 PM

PORTLAND, Oregon -- Doctors at a Portland hospital have joined some others across the nation and Canada in following a new recommendation aimed at preventing one of the deadliest forms of cancer in women.
“This is something so simple that could save a lot of lives,” said Dr. Nathalie Johnson, the Medical Director of the Legacy Cancer Institute. Johnson is recommending women who have tubal ligations or hysterectomies have their fallopian tubes removed.
"It’s because researchers have found the tubes attract cancer cells which can eventually encase the ovary," she said. "You could actually find a normal ovary wrapped in cancer and realize the cancer was starting in the fallopian tube and not the ovary."
The recommendation is supported by research on thousands of women. Legacy researcher Dr. Ann Smith-Shedev has studied the connection for more than a decade.
“We think this could cut the most common type of ovarian cancer by up to 70 percent,” Shedev said.
The Legacy Cancer Institute is the first program in Oregon to make the recommendation that women consider the fallopian tube removal if they’re scheduling a tubal ligation or hysterectomy.
“We’d like to raise awareness and hopefully it can become the standard here in Oregon and across the country,” said Johnson.


** I had several massive experimental surgeries in the early 1970's for lymphedema at Good Samaritan Hospital, which is now Legacy. My questions are, "is this really the answer?  Have you also warned your patients about the possibility of leg or abdominal lymphedema from such a surgery?"  Your peers in the 1960's at the Oregon Health Sciences University wrote a very interesting article about abdominal/leg lymphedema from an abdominal surgery. Pat**

Targeted anti-vascular therapies for ovarian cancer: current evidence.


Targeted anti-vascular therapies for ovarian cancer: current evidence.


Feb 2013

Source

Department of Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK.
Abstract
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.

Friday, February 1, 2013

Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.


Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.


Jan 2013

Source

Women's College Research Institute, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Abstract


Differentiating ovarian tumors based on developmental pathway may further our understanding of the disease. Traditionally,ovarian cancers were thought to arise from the ovarian surface epithelium; however, recent evidence suggests some tumors originate in the fallopian tube. We classified cases in a population-based case-control study (NECC) and two cohort studies (NHS/NHSII) by tumor dominance, a proxy for tissue of origin. Dominant tumors (likely ovarian origin) are restricted to one ovary or are at least twice as large on one ovary compared to the other. Ovarian cancer risk factors were evaluated in relation to dominant and non-dominant tumors (likely tubal origin) using polytomous logistic regression (NECC) or competing risks Cox models (NHS/NHSII). Results were combined using random-effects meta-analyses. Among 1,771 invasive epithelialovarian cancer cases, we observed 1,089 tumors with a dominant mass and 682 with no dominant mass. Dominant tumors were more likely to be mucinous, endometrioid, or clear cell, whereas non-dominant tumors were more likely to be serous. Tubal ligation, two or more births, endometriosis, and age were more strongly associated with dominant (RRs = 0.60, 0.83, 1.58, 1.37, respectively) than non-dominant tumors (RRs = 1.03, 0.93, 0.84, 1.14 p-difference = 0.0001, 0.01, 0.0003, 0.01, respectively). These data suggest that risk factors for tumors putatively arising from ovarian versus fallopian tube sites may differ; in particular, reproductive factors may be more important for ovarian-derived tumors. As this is the first study to evaluate ovarian cancer risk factors by tumor dominance, these results need to be validated by other studies.


Diabetes Drug May Improve Survival in Patients With Ovarian Cancer


Diabetes Drug May Improve Survival in Patients With Ovarian Cancer


Lauren M. Green
Published Online: Wednesday, January 30, 2013 

The oral diabetic medication metformin may help improve survival in patients with ovarian cancer, according to the results of a retrospective case-control study from the Mayo Clinic in Rochester, Minnesota.

Previous studies have shown promise for metformin as an anticancer compound. For this study, researchers used Mayo Clinic hospital records to identify patients with ovarian cancer who also received metformin for a minimum of 1 year at or after their cancer diagnosis (mean duration = 2.3 years; range, 1-11 years). Duration of metformin therapy prior to their cancer diagnosis was unknown.

The study’s ovarian cancer cohort comprised women with ovarian cancer who were also taking metformin (n = 72) and a randomly selected control group of patients with ovarian cancer who did not receive metformin (n = 143). Median disease-specific survival (DSS) for the entire group was 5.5 years. For the control group, the 5-year survival rate was 44%, whereas the survival rate for patients on metformin was 73% (P = .002).

Because epithelial ovarian cancer (EOC) accounts for most ovarian cancer mortality, the researchers identified a subset of patients with EOC from the initial cohort who had received metformin (n = 61) and compared these cases with a control group of patients with ovarian cancer who had not received metformin (n =178). Variables such as age, disease stage, histology, and receipt of platinum- versus non-platinum–based chemotherapy were similar between the two groups, which together comprised the EOC cohort (N = 239).

For the entire EOC cohort, the 5-year DSS rate was 52%. For the subset of EOC cases taking metformin, the DSS rate was significantly better than DSS in the control group: 67% versus 47%, respectively (P = .006). The researchers found that metformin was an independent predictor of survival, even after adjusting for body mass index, tumor grade, histology, surgical cytoreduction, disease stage, and chemotherapy (hazard ratio = 2.2; 95% CI, 1.2-3.8; P = .007).

When the EOC cohort was compared with a diabetic control group of patients with EOC whose diabetes was being treated with insulin or medications other than metformin (n = 103), 5-year DSS was lower for the diabetic control group (40%) as compared with the EOC cohort and nondiabetic controls. In this analysis, researchers also looked at 5-year DSS associated with specific antidiabetic medications. Metformin use was associated with a higher DSS rate (67%) than insulin (43%) and other antidiabetic medications (34%; P = .004).

The researchers noted that their findings are consistent with an earlier University of Chicago study reported in the January 2012 issue of Obstetrics & Gynecology, which found an association between metformin and improved recurrence-free survival in patients with ovarian cancer.

“Our study demonstrated improved survival in women with ovarian cancer who were also taking metformin,” co-lead author Sanjeev Kumar, MBBS, a fellow in Gynecologic Oncology at the Mayo Clinic, said in a statement. “Although causation could not be assessed by our retrospective study, metformin nevertheless is a strong contender for further clinical studies in ovarian cancer,” the researchers concluded.

Wednesday, January 30, 2013

Role of heparan sulfatases in ovarian and breast cancer.


Role of heparan sulfatases in ovarian and breast cancer.


2013

Source

Department of Experimental Pathology, Mayo Clinic College of Medicine Rochester, MN, USA.

Abstract


Endosulfatases HSulf-1 and -2 (also referred to as Sulf1 and -2) represent a family of enzymes that modulate heparin binding growth factor signaling. Heparan sulfatase 1 (HSulf-1) and heparan sulfatase 2 (HSulf-2) are two important 6-O endosulfatases which remove or edit 6-O sulfate residues of N-glucosamine present on highly sulfated HS. Alteration of heparan sulfatases have been identified in the context of several cancer types. Many cancer types either exhibit increased or decreased HSulfs expression at the transcript levels. Specifically, HSulf-1 was found to be downregulated in early-stageovarian tumors, hepatocellular carcinoma, and metastatic breast cancer patients. HSulf-2 was found to be upregulated in ductal carcinoma in situ and invasive ductal carcinoma, whereas limited information is present about HSulf-2 expression in different stages of ovarian cancers. Here, we review the important role of these sulfatases play in ovarian and breast cancers in terms of tumorigenesis such as angiogenesis, chemoresistance, apoptosis, growth factor signaling, hypoxia and metastasis. These recent discoveries have added significant understanding about these sulfate editing enzymes.

Sunday, January 13, 2013

Breastfeeding babies can reduce a mother's risk of Ovarian cancer by two-thirds


Breastfeeding babies can reduce a mother's risk of Ovarian cancer by two-thirds



| 

Breastfeeding her baby can reduce a mother’s risk of ovarian cancer by nearly two-thirds, according to scientists.

And the longer she continues to do it, the greater the protection against the illness.

The research adds to evidence of the benefits of natural feeding as numerous studies  have already shown it cuts the chance of  breast cancer.

More than 6,000 patients a year in the UK are diagnosed with ovarian cancer, and the illness accounts for about 5 per cent of cancer deaths in women.

It is known as the ‘silent killer’ because symptoms for many sufferers, such as feeling bloated, are non-specific and the illness may not be diagnosed until it is fairly advanced.

For the latest study, Australian scientists studied 493 women diagnosed with ovarian cancer and compared them with 472 healthy volunteers of similar age.

Each was asked how many children they had and for how long they breastfed each one.

The results showed those who breastfed a child for at least 13 months were 63 per cent less likely to develop a tumour than those who did so for less than seven months.

The more children they had, the greater the effect, said the findings, published in the American Journal of Clinical Nutrition. Mothers who had three children and breastfed for a total of 31 months or more were found to cut their chances of ovarian tumours by 91 per cent. This was compared to those feeding naturally for a total of under ten months.

Breastfeeding is thought to help as it delays ovulation, when eggs are released and the ovaries are exposed to high levels of oestrogen-rich fluid.

Some researchers believe a higher number of ovulations raises the risk of mutant cells forming, which can trigger the disease.

But surveys have shown the UK has one of the lowest breastfeeding rates in Europe.

Nearly eight in ten mothers start when their baby is born but after six weeks, this is down to half.

After six months – the recommended time for exclusive breastfeeding – it is only 26 per cent.

The main risk factors for ovarian cancer include a family history of the disease, having already had breast cancer, starting periods at a young age and being overweight.

Dr Helga Groll, of Cancer Research UK, said the findings backed up earlier evidence on the benefits of breastfeeding.

But she warned that some mothers may not accurately remember for how long they had breastfed.

Gilda Witte, chief executive of Ovarian Cancer Action, added: ‘It is proven that breastfeeding can reduce the risk of ovarian cancer.

‘It does this because it reduces ovulation for the nursing mother.

‘The risk is further reduced by each child that a woman bears.’

MailOnline


Pap Smear Detects Ovarian, Uterine Cancer

Pap Smear Detects Ovarian, Uterine Cancer

Sunday, January 6, 2013

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells.


Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells.


2012

Source

Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P.R.China.

Abstract


Ovarian cancer is a highly lethal disease with poor prognosis and especially in high-grade tumor. Emerging evidence has reported that aberrant upregulation and activation of GRB7, ERK as well as FOXM1 are closely associated with aggresivenesss of human cancers. However, the interplay between these factors in the pathogenesis of human cancers still remains unclear. In this study, we found that GRB7, ERK phosphorylation  and FOXM1 were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 , ERK phosphorylation  and FOXM1 showed a significant stepwise increase pattern along Grade 1 to Grade 3ovarian cancers. Biochemical studies using western blot analysis demonstrated that enforced expression or knockdown of GRB7 showed GRB7 could elevate the levels of ERK phosphorylation and FOXM1, whereas enforced expression of FOXM1 could not alter levels of GRB7 and ERK phosphorylation. But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly. Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo. Collectively, our findings confer that targeting GRB7/ERK/FOXM1 signaling cascade may be a promising molecular therapeutic choice in combating ovarian cancer.

Full text article

Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer.


Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer.


Jan 2013

Source

Department of Surgery, Division of Gynecologic Oncology, City of Hope, 1500 E. Duarte Road, Duarte, CA, 91010, USA, ehan@coh.org.

Abstract


OPINION STATEMENT: Treatment of epithelial ovarian cancer involves surgical management with staging or debulking surgery and chemotherapy with a platinum and taxane-containing regimen. Despite achieving a 70-80 % complete remission, patients often will recur. Novel therapies are needed to improve the treatment of ovarian cancers. Tumor angiogenesis is a critical process involved in the growth and metastasis of ovarian cancer. Numerous phase II trials with angiogenesis inhibitors have been reported and have led to the development and completion of several recent phase III trials in both upfront and recurrent ovarian cancers. Future studies will need to focus on how and when to incorporate angiogenesis inhibitors in the treatment armamentarium for ovarian cancers.

Paulinda Schimmel Babbini: Raising ovarian cancer awareness


Paulinda Schimmel Babbini: Raising ovarian cancer awareness




Often, when someone is coping with an extraordinary loss, the feelings can be all-encompassing. When Paulinda Schimmel Babbini’s daughter, Robin, died of ovarian cancer at the age of 20, instead of letting the tragic death immobilize her, Babbini made it her mission that no one else should go through what she had.

Babbini is the founder and president of The Ovarian Cancer Circle, a foundation she started in 2010 in memory of her daughter. In 2004, Robin, at age 16, was homecoming queen and co-captain of the cheerleading squad at Pacific Hills High School. That same year she also started complaining of cramps. Doctors brushed it off, saying it was her menstrual cycle. The symptoms persisted, however, and a year later she was diagnosed with stage-three ovarian cancer. Robin underwent a hysterectomy and chemotherapy treatments, and was able to enter into her first year of college at University of California, Santa Barbara. Six months later, the cancer recurred; she lost her tumultuous battle in 2006. 

Since its founding, the nonprofit Ovarian Cancer Circle, which includes 12 members, has raised more than $35,000 to fight ovarian cancer. 

“My focus for starting The Circle is to give ovarian cancer a higher public profile; to support research, educate, heighten awareness to the signs and symptoms of this cancer; and to raise funds for an early-detection test, which does not yet exist,” Babbini said. “So many lives are saved by mammograms, Pap smears and PSA tests [for prostate cancer]. But ovarian cancer is a stealth cancer, almost hidden, with few, and random, symptoms.” They are abdominal pressure, bloating, nausea, indigestion, feeling full but eating less, urinary frequency and constipation, she said. “Knowledge is critically important. I encourage women to pay attention to their bodies, know the symptoms and go to the gynecologist.”

Her group holds fundraisers twice a year and participates in numerous health fairs. They’ve hosted events at Hamburger Mary’s, featuring drag-queen bingo, along with a stand-up show at The Comedy Store in West Hollywood that showcased Sinbad as the headliner. On Feb. 21 at 11:30 a.m., Ovarian Cancer Circle is putting together a luncheon at Ruth’s Chris Steak House in Woodland Hills. The group will donate 100 percent of the proceeds to ovarian cancer research. On the Web site, theovariancancercircle.org, donations can be made by purchasing bracelets, scarves and necklaces in teal, the color designated to represent ovarian cancer, at Robin’s Store. 

Dalia Hayon, a friend, said she admires Paulinda for her strength and giving demeanor. “As a mother and grandmother, I would not have been able to bear the pain. It takes a special person and a mensch to be able to put aside her suffering, [to] be such an advocate for her girl and make sure other people are aware of it and know more about what to expect. She wasn’t expecting to get, but to give. She is a very giving person.”

For her part, Babbini said everything she does is in memory of her daughter. “Robin is my inspiration, motivation and strength. Her spirit inspires me to stay focused and, with steadfast determination, make a difference.”

Saturday, December 29, 2012

Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.


Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.


Dec 2012

Source

Department of Obstetrics and Gynaecology, Split University Hospital Centre and School of Medicine, Spinčićeva 1, 21000, Split, Croatia, boris.bacic@st.t-com.hr.

Abstract


PURPOSE:

To analyse correlation between expression of E-cadherin and clinical and pathological features and overall survival in advanced-stage serous ovarian carcinoma.

METHODS:

The expression of E-cadherin was analysed immunohistochemically in formalin-fixed, paraffin-embedded samples from 54 patients with advanced-stage serous ovarian cancer and related to clinicopathological characteristics and patients survival. The clinicopathological characteristics included the stage according to the International Federation of Gynecology and Obstetrics (FIGO), tumour differentiation, number of mitoses per 10 high-power fields (HPF), residual tumour size, and vascular invasion. Only patients with serous ovarian cancer FIGO stages III-IV were included. Overall survival (OS) was defined as time from surgery to the last follow-up date on 01.10.2010. OS was evaluated using Kaplan-Meier method, and log-rank test was used to asses the differences between the positive and E-cadherin negative group. Multivariate analysis was completed using the Cox proportional hazard regression model.

RESULTS:

E-cadherin immunoreactivity was not associated with FIGO stage, tumour grade, number of mitotic figures per 10 HPF, residual tumour volume or vascular invasion. Negative E-cadherin expression significantly predicted shorter OS (p < 0.001). The multivariate analyses showed that negative E-cadherin (p < 0.001), FIGO stage (p = 0.012) and residual tumour size >1 cm after the initial cytoreductive surgery (p < 0.001) were predictors of shorter OS.

CONCLUSION:

Negative E-cadherin expression like presence of residual tumour after primary cytoreductive surgery and higher FIGO stage seem to predict unfavourable clinical outcome in patients with advanced-stage serous ovarian cancer. Negative expression of E-cadherin was shown to be a significant independent predictor of poorer OS. E-cadherin as marker has prognostic value.

Nail toxicity associated with Paclitaxel treatment for ovarian cancer.


Nail toxicity associated with Paclitaxel treatment for ovarian cancer.


Jan 2103

Source

Park Nicollet Institute, St. Louis Park, MN.

Abstract


A 57-year-old woman named C. B. began experiencing abdominal pain and bloating. She presented to her primary physician with these symptoms, and her physician palpated an adenexal mass on pelvic examination. That prompted a computed tomography (CT) scan of the abdomen and pelvis, which demonstrated omental thickening as well as a mildly enlarged left ovary. After initial consultation with a gynecologic oncologist, C. B. was taken to surgery and a total abdominal hysterectomy bilateral salpingo-oophorectomy omentectomy partial bowel resection, and pelvic and periaortic lymph node dissection were performed. C. B. was diagnosed with stage IV ovarian cancer involving the omentum, pelvic lymph nodes, and bowel wall and was subsequently referred for postoperative chemotherapy.